ophiopogonin d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ophiopogonin D: RN given refers to (1beta,3beta,25R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	46173859
CHEBI ID	80883
MeSH ID	M0135893

Synonyms (23)

Synonym
41753-55-3
ophiopogonin d
C17042
E0022
diosgenin 3-o-(alpha-l-rhamnopyranosyl-(1-2))(beta-d-xylopyranosyl-(1-3))-beta-d-glucopyranoside
945619-74-9
CHEBI:80883
deacetylophiopogonin c
deacetylophiopogonin c,ojv-v
ophiopogonin d, >=98% (hplc)
ophiopogonind
ojv-vi
AKOS032949041
Q27151383
FS-9595
mfcd09970543
125150-67-6
HY-N0515
CS-0009054
i(2)-d-gulopyranoside, i(2)-d-xylopyranosyl o-6-deoxy-i+/--l-mannopyranosyl-(1->2)-6-deoxy-1-c-[(3i(2),14i(3/4),25r)-3-hydroxyspirost-5-en-1-yl]-
(2s,3r,4r,5r,6s)-2-[(2r,3r,4s,5s,6r)-5-hydroxy-2-[(1s,2s,4s,5'r,6r,7s,8r,9s,12s,13r,14r,16r)-16-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14-yl]oxy-6-methyl-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-y
A859337
DTXSID401317339

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" The pharmacokinetic study of ophiopogonin D in rats was then defined using the method after intravenous dosing (77."	( Quantitative determination of ophiopogonin d by liquid chromatography/electrospray ionization mass spectrometry and its pharmacokinetics in rat. Gu, SH; Hao, HP; Roberts, MS; Shang, LL; Sun, JG; Wang, GJ; Xia, CH; Yan, B; Zheng, CN, 2008)	0.35

Bioavailability

Excerpt	Reference	Relevance
" It suggested that the potential interactions of SMS with CYP 3A drug substrates should be noticed, especially the drugs whose bioavailability depends heavily on intestinal CYP3A."	( Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats. Chia-Hui Tan, E; Chiang, TY; Lee, IJ; Ueng, YF; Wang, HJ; Wang, YC; Yun, CH, 2021)	0.62

Dosage Studied

Excerpt	Relevance	Reference
" The pharmacokinetic study of ophiopogonin D in rats was then defined using the method after intravenous dosing (77."	( Quantitative determination of ophiopogonin d by liquid chromatography/electrospray ionization mass spectrometry and its pharmacokinetics in rat. Gu, SH; Hao, HP; Roberts, MS; Shang, LL; Sun, JG; Wang, GJ; Xia, CH; Yan, B; Zheng, CN, 2008)	0.35
"Rats were divided into 7 groups and dosed consecutively for 7 days with mono and combined-therapy administrations."	( A metabonomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats. Jiang, M; Kang, L; Li, Z; Liu, X; Wang, Y; Xu, L; Zhao, X, 2014)	0.4

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
steroid saponin	Any saponin derived from a hydroxysteroid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (38)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.63)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (7.89)	29.6817
2010's	18 (47.37)	24.3611
2020's	16 (42.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (2.63%)	4.05%
Observational	0 (0.00%)	0.25%
Other	37 (97.37%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dinitrochlorobenzene Dinitrochlorobenzene: A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds.. 1-chloro-2,4-dinitrobenzene : A C-nitro compound that is chlorobenzene carrying a nitro substituent at each of the 2- and 4-positions.	2.25	1	C-nitro compound; monochlorobenzenes	allergen; epitope; sensitiser
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.31	1	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	7.72	2	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.31	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.1	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	7.17	1	titanium group element atom
atorvastatin [no description available]	2.21	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
schizandrin b schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant	2.31	1
cryptotanshinone cryptotanshinone: from Salvia miltiorrhiza	7.6	1	abietane diterpenoid	anticoronaviral agent
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.15	1	amino acid zwitterion; angiotensin II	human metabolite
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2.57	2
schizandrin schizandrin: a dibenzocyclooctadiene lignan; schizandra is the plant name	7.1	1
n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide: prevents the necrosome from interacting with downstream effectors; structure in first source. necrosulfonamide : A sulfonamide that is a 3-methoxypyrazin-2-yl derivative of (E)-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide. Necrosulfonamide specifically blocks necrosis downstream of the activation of RIP3 (the receptor-interacting serine-threonine kinase 3), a key signalling molecule in the programmed necrosis (necroptosis) pathway.	2.25	1	pyrazines; sulfonamide; thiophenes	necroptosis inhibitor; neuroprotective agent
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.25	1	organonitrogen compound; organooxygen compound
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	8.14	5
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	2.57	2	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	2	1	alkaline earth metal atom; elemental barium
beta-escin [no description available]	5.08	37
ginsenoside rb1 [no description available]	2.31	1	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
schisandrol a schisandrol A: dibenzocyclooctadiene lignan from Schisandra chinensis; structure in first source	2.31	1
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	1.96	1	1,2-diacyl-sn-glycero-3-phosphocholine
11,12-epoxy-5,8,14-eicosatrienoic acid 11,12-epoxy-5,8,14-eicosatrienoic acid: RN given refers to cpd without isomeric designation. (11S,12R)-EET : An 11,12-EET in which the epoxy moiety has 11S,12R-configuration.. 11,12-EET : An EET obtained by formal epoxidation of the 11,12-double bond of arachidonic acid.	2.17	1	11,12-EET	human xenobiotic metabolite
ophiopogonin b ophiopogonin B: RN given refers to (1beta,3beta,25R)-isomer; structure given in first source	1.96	1	steroid saponin
methylophiopogonanone a methylophiopogonanone A: isolated from Ophiopogon japonicus; structure in first source	2.21	1	homoflavonoid

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	3.32	5
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	7.41	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	8.32	5
Cardiac Toxicity [description not available]	2.41	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	2.41	1
Cryptogenic Fibrosing Alveolitis [description not available]	2.6	1
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	2.6	1
Eczema, Atopic [description not available]	2.25	1
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	2.25	1
Cancer of Prostate [description not available]	2.25	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.25	1
Alloxan Diabetes [description not available]	2.93	3
Diabetic Glomerulosclerosis [description not available]	2.25	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.25	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.25	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.25	1
Extravascular Hemolysis [description not available]	2.25	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.25	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.63	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Diabetic Cardiomyopathies Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.	2.31	1
Cardiac Failure [description not available]	2.25	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.25	1
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	2.17	1
Disbacteriosis [description not available]	2.17	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.17	1
Hyperlipemia [description not available]	2.17	1
Insulin Sensitivity [description not available]	2.17	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.17	1
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.17	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.17	1
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	7.17	1
Cancer of Lung [description not available]	2.17	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.17	1
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	7.17	1
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.17	1
Injury, Myocardial Reperfusion [description not available]	2.17	1
Caffey Disease [description not available]	2.21	1
Albers-Schoenberg Disease [description not available]	2.21	1
Osteopetrosis Excessive formation of dense trabecular bone leading to pathological fractures; OSTEITIS; SPLENOMEGALY with infarct; ANEMIA; and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).	2.21	1
Cardiovascular Stroke [description not available]	2.1	1
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	7.1	1
Age-Related Osteoporosis [description not available]	2.11	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	7.11	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.04	1

chemdatabank.com